Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The c...
Gland Pharma reported revenue of 55.84 billion INR for fiscal year 2025, down 1.0% from fiscal year 2024, and net income of 6.99 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 15.06 billion INR, up 7.4% from a year before. USA was its largest region in fiscal year 2025, with 49% of revenue. Its market capitalization was 507.97 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.